Merck gets state aid for East German plant

Related tags European union Merck

The European Commission has given the go-ahead for Germany to grant
a proposed €78 million in aid to help Merck KGaA build a new
biopharmaceuticals plant for the production of oncology products in
Jena, Thuringen.

The European Commission has given the go-ahead for Germany to grant a proposed €78 million in aid to help Merck KGaA build a new biopharmaceuticals plant for the production of oncology products in Jena, Thuringen.

The German government applied for approval to give the grant in March, under the Comission's Multisectoral Framework on regional aid for large investment projects. The recipient will be Merck BioFab GmbH, part of the Merck Group, which is active in specialised chemical, pharmaceutical and laboratory products.

The project concerns the establishment of a new biopharmaceuticals plant in which oncology drugs will be produced. The candidate cancer treatments will be based on antibodies derived from cloning of animal cells and are intended to treat various forms of malignancy.

The BioFab facility is due for completion in 2006 and will include laboratories, offices, warehouse and a current Good Manufacturing Practice mammalian cell culture plant.

The total proposed aid amounts to just over 30 per cent of the total investment costs of €254 million, and well within the 35 per cent ceiling on such regional aid imposed by the Commission. According to Germany, the project will lead to the creation of 280 direct jobs and a further 211 jobs in the region, according to the EC.

"The Commission's investigation showed that the market for oncology products, in which Merck BioFab will be active, is not in decline and in fact has grown faster than the overall manufacturing industry over the last years,​" said the agency in a statement.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...